Other

Zentaris Ag

Biodics

Tgc Biomics Gmbh

Johannes Gutenberg-Universität Mainz

Jochem, Ralf

Christoph Von Eichel-Streiber

Veit Braun

Michael Moos

Franz Paul Armbruster

Stefan Tenzer

Trinad Chakraborty

Jessica Reineke

Maja Rupnik

Karina Gisch

Ralf Jochem

Harald Klein

Patrice Boquet

Monica Thelestam

Hansjörg Schild

The method for detecting and identifying a variantstrain in a sample is characterized by the following steps: (a) obtaining a sample of excreta or tissue from a human or animal patient body; (b) bringing the sample into contact with at least one antibody from each of at least three of the antibody groups group I, group II, group III, group IV, group V and group VI; (c) detecting the antibody reaction and constructing the reaction pattern; (d) comparing the reaction pattern obtained in (c) with reference patterns from knownstrains andstrains the presence of which is to be tested in the investigation test; (e) assessing the agreement between the reaction pattern obtained in (c) and the reference pattern as indicative of the presence of thestrain of the reference pattern concerned in the sample.

[object Object]

The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins inand anchoring them on the surfaces thereof. The antigenic determinants are selected according to whether they are characteristic of antigens that are expressed by the tumor cells themselves.

Therapeutic composition for use in the prevention and treatment of bone metastases

Disclosed is a diagnostic test system for detectinginfections in a sample using monoclonal antibodies specific for SipC-protein.

Test system for detecting salmonella

A method of treating a disorder characterized by an activating mutation in a Ras proto-oncogene, comprising contacting cells of a patient suffering from the disorder with a protein having the toxic activity oftoxin LT under conditions favoring inactivation of Ras by glucosylation of Ras' threonine 35 in said cell. The protein preferably is an immunotoxin that contains as a toxic domain the catalytic domain of toxin LT.

Agents useful for inactivation of Ras subfamily proteins

Disclosed is a TGC method for inducting targeted somatic transgenesis in an animal host, whereby bacteria with a foreign DNA integrated into an episomal vector release, under the control of eukaryotic regulatory elements for ulterior transcription and expression, said foreign DNA in the case of infection of a foreign organism, organ, tissue, cell line or individual cells, causing transcription and expression of foreign DNA and/or foreign protein in said location.

Recombinant listeria

The invention relates to monoclonal antibodies capable of recognizing and neutralizing epitopes from the ligand domain, the translocation domain or the catalytic domain of the enterotoxin (toxin A) and cytotoxin (toxin B) from , as well as their production and therapeutical and prophylactic applications to diseases due to the toxins.

Amino acid sequences for therapeutic and prophylactic use against diseases due to Clostridium difficile toxins

Growing community of inventors

Schweppenhausen, Germany

Christoph Von Eichel-Streiber